ProQR Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $3,843 | $6,336 | $4,476 | $3,199 |
Gross Profit | 3,843 | 5,622 | 3,781 | 3,199 |
EBITDA | -8,166 | -3,045 | -7,384 | -8,253 |
EBIT | -8,854 | -3,756 | -8,079 | -8,962 |
Net Income | -8,108 | -2,692 | -7,703 | -5,342 |
Net Change In Cash | 3,843 | 6,336 | 4,476 | 3,199 |
Free Cash Flow | -5,943 | -6,523 | -15,957 | -8,356 |
Cash | 89,401 | 78,970 | 85,792 | 119,023 |
Basic Shares | 81,665 | 81,665 | 81,571 | 78,460 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $6,514 | $4,037 | $1,354 | $243 |
Gross Profit | 6,380 | 1,561 | 1,354 | -2,194 |
EBITDA | -24,097 | -56,460 | -54,948 | -136,556 |
EBIT | -26,610 | -58,935 | -57,369 | -138,750 |
Net Income | -28,119 | -64,891 | -61,680 | -46,614 |
Net Change In Cash | 6,514 | 4,037 | 1,354 | 243 |
Free Cash Flow | 20,177 | -69,216 | -26,496 | -47,984 |
Cash | 118,925 | 94,775 | 187,524 | 75,838 |
Basic Shares | 81,011 | 71,641 | 64,182 | 50,060 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.07 |
2024-06-30 | -$0.03 |
2024-03-31 | -$0.09 |
2023-12-31 | -$0.07 |
